Tuesday December 14, 6:36 pm Eastern Time
Company Press Release
SOURCE: Mealey Publications
Mealey Publications: SmithKline
(SBH) Sued Over Lyme Vaccine
WEST CHESTER, Pa., Dec. 14 /PRNewswire/ -- A class action lawsuit filed today in
Pennsylvania claims the vaccine that prevents Lyme Disease causes an incurable form of
autoimmune arthritis and, for some, could produce symptoms far worse than those brought on by
the illness. ``Mealey's Litigation Report: Drug and Medical Devices'' informed subscribers about
the complaint today.
The complaint, filed in Chester County Court of Common Pleas, alleges SmithKline Beecham
(NYSE: SBH - news), manufacturers of the widely touted LYMErix vaccine, failed to warn
doctors and the general public that nearly 30 percent of the population was pre-disposed to a
degenerative autoimmune syndrome, which the lawsuit says is triggered by contents of the
``Once this autoimmune reaction is triggered, it cannot be cured and can only be treated
symptomatically for the remainder of the vaccine recipient's life,'' the complaint says.
According to the class action, SmithKline (SBH) used high concentrations of a surface protein
called OspA as the foundation for its vaccine. When bitten by a Lyme infected parasite, humans
are not exposed to OspA protein. The levels of OspA that enter the bloodstream at any phase of
the three-dose LYMErix vaccine, however, place patients classified by genetic type HLA-DR4+
at risk of developing a condition referred to as ``treatment-resistant'' Lyme Arthritis, the lawsuit
Despite this ``well documented relationship'' between OspA and treatment-resistant Lyme
Arthritis, SmithKline neglected to include the information in its widely disseminated promotional
literature and insisted LYMErix was safe and generally well tolerated, the class action says.
About one-third of the general population is HLA-DR4+ and risks contracting the arthritic
condition when exposed to the vaccine, according to the complaint. The HLA-DR4+ trait is easily
detected by a routine blood test; however, SmithKline never recommended that doctors screen for
the trait before administering the vaccine, the lawsuit alleges.
The complaint further alleges that patients who are infected with Lyme bacteria when they
receive LYMErix -- whether asymptomatic or in the early stages of infection -- could suffer
symptoms more progressive and enhanced than if they had not received the vaccine.
SmithKline, the class action says, also neglected to inform doctors and the general public that
periodic booster shots beyond the series of three vaccinations would be necessary to maintain
immunity to the disease.
The class action includes counts of negligence, unfair trade practices and a bid for medical
monitoring of those who are placed at risk of developing autoimmune arthritis but have not yet
been diagnosed with the condition.
The class action complaint was filed by Stephen A. Sheller and Albert J. Brooks Jr. of Sheller,
Ludwig & Badey in Philadelphia.
Sheller said that in the wake of filing the class action, he expects to file claims on behalf of
individuals who received the LYMErix vaccine and are now suffering from the autoimmune
For more information about Mealey Publications, log on to www.mealeys.com or call
1-800-MEALEYS or 610-768-7800, or contact the Company via e-mail at firstname.lastname@example.org .
SOURCE: Mealey Publications
--------------------------- ONElist Sponsor ----------------------------
Got a question about pediatric medicine? Dieting? Elder care?
Ask a real expert at www.ExpertCentral.com
With over 4700 experts, the Web's largest question and answer resource
<a href=" http://clickme.onelist.com/ad/expertcentral7 ">Click Here</a>
Any information obtained here is not to be construed as medical or legal
advice. The decision to vaccinate and how you implement that decision is
yours and yours alone.
To unsubscribe or change your subscription options, go to the Onelist website